Search Results

You are looking at 1 - 10 of 291 items for :

  • "early detection" x
  • All content x
Clear All
Full access

Mark H. Kawachi, Robert R. Bahnson, Michael Barry, J. Erik Busby, Peter R. Carroll, H. Ballentine Carter, William J. Catalona, Michael S. Cookson, Jonathan I. Epstein, Ruth B. Etzioni, Veda N. Giri, George P. Hemstreet III, Richard J. Howe, Paul H. Lange, Hans Lilja, Kevin R. Loughlin, James Mohler, Judd Moul, Robert B. Nadler, Stephen G. Patterson, Joseph C. Presti, Antoinette M. Stroup, Robert Wake, and John T. Wei

Prostate Cancer Early Detection Clinical Practice Guidelines in Oncology NCCN Categories of Evidence and Consensus Category 1: The recommendation is based on high-level evidence (e.g., randomized controlled trials) and there is uniform

Full access

Peter R. Carroll, J. Kellogg Parsons, Gerald Andriole, Robert R. Bahnson, Daniel A. Barocas, Erik P. Castle, William J. Catalona, Douglas M. Dahl, John W. Davis, Jonathan I. Epstein, Ruth B. Etzioni, Thomas Farrington, George P. Hemstreet III, Mark H. Kawachi, Paul H. Lange, Kevin R. Loughlin, William Lowrance, Paul Maroni, James Mohler, Todd M. Morgan, Robert B. Nadler, Michael Poch, Chuck Scales, Terrence M. Shaneyfelt, Marc C. Smaldone, Geoffrey Sonn, Preston Sprenke, Andrew J. Vickers, Robert Wake, Dorothy A. Shead, and Deborah Freedman-Cass

Prostate Cancer Early Detection provide a set of sequential recommendations detailing a screening and evaluation strategy for maximizing the detection of prostate cancer that is potentially curable and that, if left undetected, represents a risk to the

Full access

Peter R. Carroll, J. Kellogg Parsons, Gerald Andriole, Robert R. Bahnson, Daniel A. Barocas, William J. Catalona, Douglas M. Dahl, John W. Davis, Jonathan I. Epstein, Ruth B. Etzioni, Veda N. Giri, George P. Hemstreet III, Mark H. Kawachi, Paul H. Lange, Kevin R. Loughlin, William Lowrance, Paul Maroni, James Mohler, Todd M. Morgan, Robert B. Nadler, Michael Poch, Chuck Scales, Terrence M. Shanefelt, Andrew J. Vickers, Robert Wake, Dorothy A. Shead, and Maria Ho

to: Integrate into professional practice the updates to NCCN Guidelines for Prostate Cancer Early Detection Describe the rationale behind the decision-making process for developing the NCCN Guidelines for Prostate Cancer Early Detection

Full access

Peter R. Carroll, J. Kellogg Parsons, Gerald Andriole, Robert R. Bahnson, Erik P. Castle, William J. Catalona, Douglas M. Dahl, John W. Davis, Jonathan I. Epstein, Ruth B. Etzioni, Thomas Farrington, George P. Hemstreet III, Mark H. Kawachi, Simon Kim, Paul H. Lange, Kevin R. Loughlin, William Lowrance, Paul Maroni, James Mohler, Todd M. Morgan, Kelvin A. Moses, Robert B. Nadler, Michael Poch, Chuck Scales, Terrence M. Shaneyfelt, Marc C. Smaldone, Geoffrey Sonn, Preston Sprenkle, Andrew J. Vickers, Robert Wake, Dorothy A. Shead, and Deborah A. Freedman-Cass

activity, participants will be able to: Integrate into professional practice the updates to NCCN Guidelines for Prostate Cancer Early Detection Describe the rationale behind the decision-making process for developing the NCCN Guidelines for Prostate

Full access

David E. Misek, Tasneem H. Patwa, David M. Lubman, and Diane M. Simeone

JA . Early detection of unsuspected colon cancers in asymptomatic people . Dis Colon Rectum 1993 ; 36 : 411 . 14. Mandel JB Church JH Snover TR . Reducing mortality from colorectal cancer by screening for fecal occult blood. Minnesota

Full access

Peter H. Carroll and James L. Mohler

“There may be a cancer subject that is more controversial than the screening and early detection of prostate cancer, but I don't know what that is,” said Peter H. Carroll, MD, MPH, Professor and Chair, Department of Urology, UCSF Helen Diller

Full access

Ohio State University Comprehensive Cancer Center – James Cancer Hospital and Solove Research Institute

Prostate cancer is the most commonly diagnosed cancer in American men and the third leading cause of cancer-related deaths. However, the decision whether to pursue early detection of prostate cancer is complex; because not all men with prostate cancer will die of this disease, treatment is not necessary for some. These guidelines are intended to help men and clinicians choose a program for early detection of prostate cancer and make decisions about the need for prostate biopsy.

For the most recent version of the guidelines, please visit NCCN.org

Full access

Peter R. Carroll and Andrew J. Vickers

, and active surveillance for men with low-risk disease. Both Drs. Carroll and Vickers are members of the NCCN Guidelines Panel for Prostate Cancer Early Detection. Randomized Trials on PSA Screening The results of 2 key trials (from the United

Full access

Andrew J. Vickers

, including those related to early detection. Even an article concluding that there was “little justification” for the use of PSA velocity reported that PSA velocity was a statistically significant ( P <.001) predictor in a multivariable model. 1 However

Full access

Prostate cancer is the most commonly diagnosed cancer in American men and the second leading cause of cancer deaths. In 2004, nearly 20 million men in the United States will be confronted with important decisions regarding early detection for prostate cancer. In brief, the dilemma is that because not all men with prostate cancer die of the disease, treatment is not necessary for some patients. However, an estimated 29,900 patients will die of prostate cancer in 2004. Therefore, differentiating between patients whose cancer is clinically insignificant and those whose disease will progress is a challenge. The NCCN Prostate Cancer Early Detection Clinical Practice Guidelines in Oncology provide a set of sequential recommendations detailing a screening and subsequent work-up strategy for maximizing the detection of prostate cancer in an organ-confined state while attempting to minimize unnecessary procedures.

For the most recent version of the guidelines, please visit NCCN.org